The highest dose of BAN2401, an investigational drug for early Alzheimer disease, significantly slowed cognitive decline by 30% compared with placebo at 18 months, according to detailed results from a phase 2 randomized trial presented at the Alzheimer Association International Conference in July.
No takes yet. Share an insight, caveat, or question.
Jennifer Abbasi (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: